[1]孟旭英,范振迁,郭剑超.利拉鲁肽与格列美脲治疗2型糖尿病的系统评价[J].国际内分泌代谢杂志,2016,36(06):380-383，387.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
　Meng Xuying,Fan Zhenqian,Guo Jianchao..Effects of liraglutide versus glimepiride for type 2 diabetes mellitus: a systematic review[J].International Journal of Endocrinology and Metabolism,2016,36(06):380-383，387.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
点击复制

利拉鲁肽与格列美脲治疗2型糖尿病的系统评价()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年06期
页码:
380-383，387
栏目:
荟萃分析
出版日期:
2016-11-20

文章信息/Info

Title:
Effects of liraglutide versus glimepiride for type 2 diabetes mellitus: a systematic review
作者:
孟旭英; 范振迁; 郭剑超
300211 天津医科大学第二医院内分泌科
Author(s):
Meng Xuying;  Fan Zhenqian;  Guo Jianchao.
Department of Endocrinology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
关键词:
利拉鲁肽;  格列美脲;  二甲双胍;  2型糖尿病;  系统评价
Keywords:
Liraglutide;  Glimepiride;  Metformin;  Type 2 diabetes mellitus;  Systematic review
DOI:
10.3760/cma.j.issn.1673-4157.2016.06.05
摘要:
目的 系统评价利拉鲁肽与格列美脲联合二甲双胍治疗2型糖尿病(T2DM)的有效性和安全性。方法 计算机检索PubMed、EMbase、The Cochrane Library、WanFang Database、CBM和CNKI数据库,纳入利拉鲁肽与格列美脲联合二甲双胍治疗T2DM的随机对照试验(RCT),检索时限截至2016年1月。由2位研究者按照纳入与排除标准筛选文献、提取资料、进行质量评价,采用RevMan5.3软件进行荟萃分析。结果 共纳入13个RCT。荟萃分析结果显示:与格列美脲联合二甲双胍组相比,利拉鲁肽联合二甲双胍组能更有效地降低HbA1c(WMD:-0.36, 95% CI: -0.67～-0.06, P=0.02)及体重(WMD:-3.11, 95% CI:-3.72～-2.51, P<0.000 01); 低血糖发生率低(WMD:-0.15, 95% CI:-0.19～-0.11, P<0.000 01); 但胃肠道等不良反应发生率更高(WMD:0.18, 95% CI:0.09～0.27, P<0.000 1); 降低空腹及餐后血糖效果相当。结论 与格列美脲联合二甲双胍组相比,利拉鲁肽联合二甲双胍组能更好的控制血糖、降低体重且低血糖发生率低。
Abstract:
Objective The efficacy and safety of liraglutide and glimepiride in combination with metformin in the treatment of type 2 diabetes mellitus(T2DM)were evaluated using systematic review. Methods Databases including Pubmed, EMbase, The Cochrane Library, WanFang Database, CBM and CNKI(updated to January, 2016)were searched to collect randomized controlled trials which compared the effects of liraglutide with glimepiride in combination with metformin in T2DM. Two researchers selected the documents, extracted the data and conducted the quality assessment according to literature inclusion and elimination standards. RevMan 5.3 was used for the meta-analysis.Results A total of 13 randomized controlled trials were included. Compared with glimepiride combined metformin group, liraglutide combined metformin group reduced HbA1c(WMD: -0.36, 95% CI: -0.67--0.06, P=0.02)and weight effectively(WMD:-3.11, 95% CI:-3.72--2.51, P<0.000 01), and had low incidence of hypoglycemia(WMD:-0.15, 95% CI: -0.19--0.11, P<0.000 01), but the incidence of gastrointestinal adverse reactions was higher(WMD:0.18, 95% CI:0.09-0.27, P<0.000 1). There was no significant difference in fasting and postprandial blood glucose between two groups. Conclusion Compared with glimepiride combined metformin group, liraglutide combined metformin group has more advantages in blood glucose control and weight loss while has low incidence of hypoglycemia.

参考文献/References:

[1] Yang W, Lu J, Weng J,et al. Prevalence of diabetes among men and women in China[J].N Engl J Med, 2010,362(12):1090-1101. DOI: 10.1056/NEJMoa0908292.
[2] 刘洋,王雪鹰,赵锦.2型糖尿病应用利拉鲁肽与格列美脲联合二甲双胍治疗效果分析[J].中外医疗, 2015,(5):113-114. DOI:10.3969/j.issn.1674-0742.2015.05.054.
[3] Nauck M, Frid A, Hermansen K,et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care, 2009,32(1):84-90. DOI: 10.2337/dc08-1355.
[4] Nauck M, Frid A, Hermansen K,et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study[J].Diabetes Obes Metab, 2013,15(3):204-212. DOI: 10.1111/dom.12012.
[5] Yang W, Chen L, Ji Q,et al. Liraglutide provides similar glycaemic control as glimepiride(both in combination with metformin)and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial[J].Diabetes Obes Metab, 2011,13(1):81-88. DOI: 10.1111/j.1463-1326.2010.01323.x.
[6] 邱兴德. 列美脲与利拉鲁肽治疗初诊2型糖尿病疗效对比研究[J]. 医药论坛杂志, 2014,9,35(9):56-57.
[7] 杨文英,刘晓民,马建华,等.利拉鲁肽与格列美脲联合二甲双胍对2型糖尿病的疗效和安全性比较[J]. 中华糖尿病杂志,2011,3(6):457-462. DOI:10.3760/cma.j.issn.1674-5809.2011.06.004.
[8] 刘波. 利拉鲁肽与格列美脲联合二甲双胍治疗老年2型糖尿病疗效比较[J]. 中国老年学杂志,2013,33(6):1396-1397. DOI:10.3969/j.issn.1005-9202.2013.06.080.
[9] 周保安.利拉鲁肽与格列美脲治疗2型糖尿病伴肥胖患者的疗效比较[J]. 实用糖尿病杂志,2014,10(2):27-29.
[10] Li D, Xu X, Zhang Y,et al. Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes[J].Diabetes Res Clin Pract, 2015,110(2):224-228. DOI: 10.1016/j.diabres.2015.05.051.
[11] Chiefari E, Capula C, Vero A,et al. Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy[J].Diabetes Technol Ther, 2015,17(7):468-474. DOI: 10.1089/dia.2014.0412.
[12] Nauck MA, Hompesch M, Filipczak R,et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes[J].Exp Clin Endocrinol Diabetes, 2006,114(8):417-423. DOI:10.1055/s-2006-924230.
[13] 郭剑津,任伟,秦洁,等. 二甲双胍联合利拉鲁肽对2 型糖尿病同型半胱氨酸等心血管危险因素的影响[J]. 中华临床医师杂志(电子版),2015,9(1):59-62. DOI:10.3877/cma.j.issn.1674-0785.2015.01.005.
[14] 邹辉彬. 利拉鲁肽与格列美脲联合二甲双胍对2 型糖尿病的疗效和安全性比较[J]. 糖尿病新世界,2014,9:10.
[15] Korytkowski M, Thomas A, Reid L,et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes[J].Diabetes Care, 2002,25(9):1607-1611.
[16] Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[J].Mol Cell Endocrinol, 2009,297(1-2):137-140. DOI: 10.1016/j.mce.2008.11.018.
[17] Nauck MA, Niedereichholz U, Ettler R,et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans[J].Am J Physiol,1997,273(5 Pt 1):E981-E988.
[18] Arai K, Matoba K, Hirao K,et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients[J].Endocr J, 2010,57(6):499-507.
[19] Madsbad S, Schmitz O, Ranstam J,et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide(NN2211): a 12-week, double-blind, randomized, controlled trial[J].Diabetes Care, 2004,27(6):1335-1342.
[20] Zinman B, Gerich J, Buse JB,et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met+TZD)[J].Diabetes Care, 2009,32(7):1224-1230. DOI: 10.2337/dc08-2124.

相似文献/References:

[1]刘璠,张趁儒,周慧敏,等.2型糖尿病患者利拉鲁肽替代预混胰岛素治疗的有效性和安全性分析[J].国际内分泌代谢杂志,2014,(04):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
　Liu Fan,Zhang Chenru,Zhou Huimin,et al.Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(06):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
[2]陈妹妹,梁瑜祯,李争明,等.利拉鲁肽对白色脂肪的作用[J].国际内分泌代谢杂志,2020,40(05):331.[doi:10.3760/cma.j.cn121383-20191206-12014]
　Chen Meimei,Liang Yuzhen,Li Zhengming,et al.Effect of liraglutide on white fat[J].International Journal of Endocrinology and Metabolism,2020,40(06):331.[doi:10.3760/cma.j.cn121383-20191206-12014]
[3]庄伟 王志强 王正杰 安淑华.利拉鲁肽对2型糖尿病患者血清miRNA表达及相关细胞信号通路蛋白的影响[J].国际内分泌代谢杂志,2022,42(04):307.[doi:10.3760/cma.j.cn121383-20220218-02038]
　Zhuang Wei,Wang Zhiqiang,Wang Zhengjie,et al.Effects of liraglutide on miRNAs expression profile and related cell signaling pathways in T2DM patients[J].International Journal of Endocrinology and Metabolism,2022,42(06):307.[doi:10.3760/cma.j.cn121383-20220218-02038]

更新日期/Last Update: 2016-12-20